These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33988236)

  • 1. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
    Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
    Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
    Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
    Khoury A; Pagan KA; Farland MZ
    Ann Pharmacother; 2021 Feb; 55(2):222-229. PubMed ID: 32633548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.
    Pergola PE; Kopyt NP
    Am J Kidney Dis; 2021 Dec; 78(6):846-856.e1. PubMed ID: 34029682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
    Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.
    Schmidt C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Howaldt S; Stallmach A; Büning C;
    Aliment Pharmacol Ther; 2016 Aug; 44(3):259-70. PubMed ID: 27237709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.
    Gasche C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Büning C; Howaldt S; Stallmach A;
    Inflamm Bowel Dis; 2015 Mar; 21(3):579-88. PubMed ID: 25545376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis.
    Tabish M; Agarwal S; Gopi S; Rana R; Ahmed S; Gunjan D; Sharma S; Saraya A
    Am J Gastroenterol; 2024 Oct; 119(10):2061-2069. PubMed ID: 38517084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.
    Qunibi WY; Martinez C; Smith M; Benjamin J; Mangione A; Roger SD
    Nephrol Dial Transplant; 2011 May; 26(5):1599-607. PubMed ID: 20929915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
    Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
    JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP).
    Breymann C; Milman N; Mezzacasa A; Bernard R; Dudenhausen J;
    J Perinat Med; 2017 May; 45(4):443-453. PubMed ID: 27278921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.
    Bokemeyer B; Krummenerl A; Maaser C; Howaldt S; Mroß M; Mallard N
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):229-238. PubMed ID: 27101422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.